TD Cowen analyst Ritu Baral reiterated a Buy rating on Terns Pharmaceuticals (NASDAQ: TERN).The analyst commented, "TERN hosted an investor ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments

Terns Pharmaceuticals (TERN) PT Raised to $30 at Jefferies Following +16% Gain TodaySeptember 9, 2024 4:00 PM